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In immunobullous disease, the host
immune system disrupts adhesive inter-
actions in the skin, typically leading to
clinical blister formation. The patho-
physiology of these diseases has been
an active area of investigation. The
mechanisms by which these disorders
lead to loss of adhesion are variable
and disease dependent; however, gen-
eral principles have been described.
The term ‘‘subepidermal blistering
disease’’ applies to several disorders
that share the clinical appearance of
vesicles and bulla, the histologic find-
ing of subepidermal blistering, and in
situ deposition of autoantibodies at the
dermal–epidermal junction. This group
of diseases includes bullous pemphi-
goid (BP), cicatricial pemphigoid,
herpes gestationis, dermatitis herpeti-
formis, linear IgA disease, lichen pla-
nus pemphigoides, epidermolysis
bullosa acquisita (EBA), and bullous
systemic lupus erythematosus. Intraepi-
dermal blistering diseases are charac-
terized by acantholysis, loss of
adhesion between adjacent epidermal
keratinocytes, and deposition of immu-
noreactants at the keratinocyte cell
membrane. The protypical intraepider-
mal autoimmune blistering diseases are
pemphigus vulgaris (PV) and pemphi-
gus foliaceus (PF).
The autoimmune nature of these
disorders began to be appreciated in
the late 1960s when Jordon and Beut-
ner used immunofluorescent techni-
ques to demonstrate that BP patients
have circulating and tissue-bound auto-
antibodies directed against antigens of
the basement membrane zone. Use of
these autoantibodies as a screening tool
facilitated the identification of the
target autoantigens. Using such an
approach, Stanley et al. (1981, 1988)
first characterized BP antigens at the
molecular level and cloned the BP230
cDNA. Subsequently, cDNAs encoding
BP180 (the autoantigen for BP, cicatri-
cial pemphigoid, herpes gestationis,
lichen planus pemphigoides, and linear
IgA disease), laminin 5 (the autoantigen
for cicatricial pemphigoid), and type VII
collagen (the autoantigen for EBA and
bullous systemic lupus erythematosus)
were also cloned and characterized.
ROLE OF ANTIBODY CLASS AND SUBCLASS
Although there began to be an estab-
lished relationship between the pre-
sence of these targeted autoantibodies
and blistering diseases, it was not until
the early 1980s that a direct pathogenic
role for these self-directed Igs was
demonstrated. Anhalt et al. (1982)
pioneered the use of the passive transfer
animal model to test the pathogenicity
of pemphigus autoantibodies. Intraper-
itoneal injections of PV IgG and PF IgG
induced intraepidermal blisters in neo-
natal mice, duplicating the key clinical
and histological features of the human
diseases. This passive transfer model
provided a means to define in detail the
humoral immune response. For exam-
ple, Rock et al. (1989) used this system
to demonstrate subclass specificity
when they demonstrated that IgG4.
subclass autoantibodies were patho-
genic in pemphigus. Using IgG passive
transfer experiments, Amagai et al.
(1992) showed that IgG autoantibodies
against desmoglein (Dsg)1 and Dsg3 are
pathogenic and are important in indu-
cing blister formation in pemphigus.
The success of the passive transfer
mouse model in pemphigus led to
similar investigations in pemphigoid
and EBA; however, when applied to
pemphigoid, similar approaches failed
to demonstrate the pathogenicity of
pemphigoid autoantibodies due to the
lack of cross-reactivity between murine
and human autoantigens. As an alter-
native, Liu et al. (1993) generated rabbit
anti-murine BP180 IgG, which induced
BP in mice. With the same strategy,
animal models for cicatricial pemphi-
goid and EBA were also developed by
passive transfer of rabbit anti-laminin 5
and rabbit anti-type VII collagen IgG in
mice, respectively (Lazarova et al, 1996;
Sitaru et al, 2005). Subsequently, anti-
laminin 5, anti-type VII collagen, and
anti-BP180 autoantibodies from patients
were proved directly to be pathogenic
in animal models (Lazarova et al, 2000;
Woodley et al, 2006; Nishie et al.,
2007). Besides IgG autoantibodies, anti-
BP180 IgE antibodies were also shown
to be pathogenic in human skin graft
models (Zone et al, 2007; Fairley et al,
2007).
ROLE OF COMPLEMENT
Although local complement activation
is universal in immunobullous diseases,
PV and PF autoantibodies induce epi-
dermal cell detachment in the mouse
model independent of complement
activation. In contrast, the classical
pathway is required for experimental
BP, whereas the alternative pathway is
critical in experimental EBA.
ANTIBODY-MEDIATED INJURY
In the rabbit anti-mBP180 IgG-induced
BP model, pathogenic antibodies
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trigger a complement-, mast cell-, and
neutrophil-dependent inflammatory
cascade, which causes a protease–pro-
tease inhibitor imbalance. Increased
proteolytic enzymes then cleave
BP180 and other extracellular matrix
proteins, leading to dermal–epidermal
junction separation. However, in the
anti-laminin 5-induced dermal–epider-
mal junction separation, complement
and mast cells are dispensable.
ROLE OF T CELLS
T lymphocytes are crucial in initiating
autoimmune responses. Wucherpfen-
nig et al. (1995) first demonstrated that
T cells from PV patients with active
disease responded to Dsg3 extracellu-
lar peptides. Subsequently, Budinger
et al. (1998) identified Th1 and Th2
responses against the BP180 ectodo-
main in BP. Activation of autoreactive
T cells is restricted by distinct HLA
class II alleles that are prevalent in
patients with these diseases. These T
cells may be important in the activation
and differentiation of B cells that
produce pathogenic autoantibodies.
ROLE OF SIGNAL TRANSDUCTION
In pemphigoid, binding of antibody to
BP180 initiates a series of extracellular
inflammatory events that leads to pro-
teolysis of BP180 by human neutrophil
elastase. In contrast, in pemphigus
antibody binding to Dsg does not
require inflammatory components to
mediate blister formation. Binding of
pemphigus IgG to Dsg appears to
initiate a series of events within the
target keratinocyte that leads to subse-
quent loss of cell–cell adhesion.
Several key observations support the
idea that energy-requiring cellular
events are required for PV or PF IgG
to induce acantholysis. In cultured
cells, Kowalczyck’s group showed that
PV IgG-mediated disruption of kerati-
nocyte adhesion and Dsg3 internaliza-
tion were temperature dependent,
occurring at 37 1C, but not at 4 1C,
despite the fact that PV IgG continued
to bind to the keratinocyte cell surface
at 4 1C (Calkins et al., 2006). Additional
evidence that energy-dependent pro-
cesses within live cells are required
for pemphigus IgG to induce loss of
adhesion comes from the investigation
of the effects of PF IgG on the binding
of Dsg1-coated beads to cultured Ha-
Cat cells. Only when PF IgG bound to
metabolically active keratinocytes was
bead release observed; bead release
did not occur if the metabolically inert
Dsg1-coated beads were first incubated
with Dsg1-specific PF IgG (Waschke
et al., 2005).
In 1995 Kitajima proposed that
binding of pemphigus IgG to human
squamous-cell carcinoma cell lines
activated intracellular signaling (Seishi-
ma et al., 1995). Using a biochemical
screen, subsequent studies by our group
demonstrated that binding of PV IgG to
keratinocyte cell-surface Dsg3 activated
phosphorylation of p38MAPK and heat-
shock protein 27 within the target
keratinocyte both in vitro and in vivo.
Inhibition of p38MAPK blocked the
ability of PV IgG to induce cytoskeletal
changes that precede acantholysis. In
the passive transfer mouse model of PV,
inhibition of p38MAPK blocked the
ability of PV IgG to induce blistering
in vivo, suggesting a causal role for
signaling in the mechanism by which
these antibodies induce loss of cell–cell
adhesion and further suggesting that
blockade of this enzyme in patients
might prove an effective strategy for
treating pemphigus (Berkowitz et al.,
2006). Both the GTPase RhoA and
plakoglobin have been mechanistically
implicated in the cascade of intracel-
lular events induced by pemphigus IgG.
Keratinocytes from plakoglobin knock-
out mice do not retract their keratin
intermediate filaments or lose adhesion
when exposed to PV IgG, suggesting a
critical role for this catenin in PV IgG-
mediated acantholysis (Caldelari et al.,
2001). Waschke et al.’s observations
that (1) incubation of cultured cells with
PV or PF IgG reduced the activity of
Rho A, (2) the Rho A activator cytotoxic
necrotizing factor-y blocked pemphigus
IgG-induced skin splitting, and (3)
modulation of RhoA activity by PF IgG
is p38MAPK dependent collectively
suggest that RhoA may be a down-
stream target of p38MAPK in this
signaling cascade (Waschke et al.,
2006).
Over 5 decades of active investiga-
tion by numerous labs around the
world have contributed to our current
understanding of autoimmune blister-
ing diseases. Although much work
remains in order to precisely define
how these autoimmune responses de-
velop and cause tissue injury, detailed
maps of the pathophysiologic mechan-
isms are beginning to emerge and
provide opportunities for developing
specific targeted therapies.
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